Cited 0 times in
Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon, HC | - |
dc.contributor.author | Cheong, JY | - |
dc.contributor.author | Cho, SW | - |
dc.contributor.author | Choi, JM | - |
dc.contributor.author | Hong, SP | - |
dc.contributor.author | Kim, SO | - |
dc.contributor.author | Yoo, WD | - |
dc.date.accessioned | 2010-12-03T01:44:01Z | - |
dc.date.available | 2010-12-03T01:44:01Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/390 | - |
dc.description.abstract | BACKGROUND: To evaluate the effect of reversion to YMDD wild-type on emergence of adefovir (ADV)-resistant mutation and antiviral activity of ADV in lamivudine (LAM)- resistant patients.
METHODS: We determined YMDD mutations and ADV-resistant mutations before and every 3 months during ADV monotherapy in 33 LAM-resistant patients using the restriction fragment mass polymorphism (RFMP) method. RESULTS: Reversion to pure YMDD wild-type hepatitis B virus (HBV) occurred in 6% (2/33), 9% (3/33), 20% (4/20) and 35% (6/17) of patients after 12, 24, 36 and 48 weeks, respectively. Five (29%) patients were found to have pure YMDD mutants at 48 weeks of therapy. Among 33 patients, 4 (12%) patients developed ADV-resistant mutations at 48 weeks of therapy. Adefovir-resistant mutants emerged in all patients after reversion to YMDD wild-type HBV. The mean serum HBV reductions, evaluated at 24 weeks of therapy, were not different between patients with and without reversion to YMDD wild-type HBV (-3.1 log(10) copies/mL vs-3.4 log(10) copies/mL, P > 0.05). CONCLUSIONS: ADV-resistant mutations emerged after reversion to YMDD wild-type in LAM-resistant patients who received ADV monotherapy. Thus, ADV add-on therapy may be necessary to reduce the incidence of developing ADV resistance in patients with LAM resistance. | - |
dc.language.iso | en | - |
dc.subject.MESH | Adenine | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antiviral Agents | - |
dc.subject.MESH | DNA, Viral | - |
dc.subject.MESH | Drug Resistance, Multiple, Viral | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hepatitis B | - |
dc.subject.MESH | Hepatitis B virus | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lamivudine | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Phosphonic Acids | - |
dc.subject.MESH | Polymorphism, Restriction Fragment Length | - |
dc.subject.MESH | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Viral Load | - |
dc.title | Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. | - |
dc.type | Article | - |
dc.identifier.pmid | 19196395 | - |
dc.contributor.affiliatedAuthor | 정, 재연 | - |
dc.contributor.affiliatedAuthor | 조, 성원 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1111/j.1440-1746.2008.05570.x | - |
dc.citation.title | Journal of gastroenterology and hepatology | - |
dc.citation.volume | 24 | - |
dc.citation.number | 1 | - |
dc.citation.date | 2009 | - |
dc.citation.startPage | 49 | - |
dc.citation.endPage | 54 | - |
dc.identifier.bibliographicCitation | Journal of gastroenterology and hepatology, 24(1). : 49-54, 2009 | - |
dc.identifier.eissn | 1440-1746 | - |
dc.relation.journalid | J008159319 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.